Form 4: Timothy A. Springer Reports Changes in Beneficial Ownership of Cartesian Therapeutics, Inc. (RNAC)

Sentiment:

SEC Form 4 Filing


Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc., filed a Form 4 disclosing transactions involving Series B Non-Voting Convertible Preferred Stock and Common Stock.

Summary

  • On July 2, 2024, Timothy A. Springer reported acquiring 1,636,832 shares of Series B Non-Voting Convertible Preferred Stock at $20 per share.
  • On the same date, Springer also reported acquiring 721,361 shares of Series B Non-Voting Convertible Preferred Stock indirectly through TAS Partners LLC at $20 per share.
  • Additionally, 1,307 shares of Series B Non-Voting Convertible Preferred Stock were acquired indirectly by Springer's wife at $20 per share on July 2, 2024.
  • Springer directly owns 4,379,899 shares of Common Stock.
  • Springer indirectly owns 1,927,630 shares of Common Stock through TAS Partners LLC.
  • Springer's wife indirectly owns 3,493 shares of Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a regulatory filing reporting transactions. The increased holdings could be seen as a positive, but without further context, it's difficult to assess the overall impact.

Positives

  • The reporting person's increased investment in Series B Non-Voting Convertible Preferred Stock could be interpreted as a positive signal.

Industry Context

This filing is a routine disclosure required by the SEC for insiders who trade in their company's stock. It provides transparency to the market regarding the transactions of directors and principal shareholders.

Comparison to Industry Standards

  • Form 4 filings are standard practice for publicly traded companies and their insiders.
  • The information disclosed is consistent with SEC regulations and reporting requirements.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding insider transactions.
  • The transactions may influence investor sentiment depending on how they interpret the insider's actions.

Key Dates

DateDescription
07/02/2024Date of earliest transaction: Acquisition of Series B Non-Voting Convertible Preferred Stock and indirect acquisitions.
07/05/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.